Xeris to Acquire Strongbridge Pipeline, Including Recorlev

Xeris to Acquire Strongbridge Pipeline, Including Recorlev

295128

Xeris to Acquire Strongbridge Pipeline, Including Recorlev

Xeris Pharmaceuticals and Strongbridge Biopharma have entered an agreement in which Xeris will acquire Strongbridge, forming a new entity called Xeris Biopharma Holdings. Following the transaction, Xeris also will acquire Strongbridge’s pipeline, which includes Recorlev (levoketoconazole), an investigational treatment for endogenous Cushing’s syndrome. “Strongbridge’s attractive rare disease portfolio and capabilities are highly complementary with Xeris. We look forward to welcoming the Strongbridge team to Xeris and leveraging our differentiated portfolios and technologies to help the…

You must be logged in to read/download the full post.